Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

Core Viewpoint - Amphastar Pharmaceuticals (AMPH) is expected to report a year-over-year decline in earnings due to lower revenues for the quarter ended September 2025, with the consensus outlook indicating a potential impact on stock price based on actual results compared to estimates [1][2]. Financial Expectations - The consensus estimate for Amphastar's quarterly earnings is $0.77 per share, reflecting a year-over-year decrease of 19.8%. Revenues are anticipated to be $184.53 million, down 3.5% from the same quarter last year [3]. - Over the last 30 days, the consensus EPS estimate has been revised 1.71% higher, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Amphastar is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -4.55%, indicating a bearish outlook from analysts [12]. - The stock currently holds a Zacks Rank of 3, making it challenging to predict a beat on the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Amphastar exceeded the expected earnings of $0.71 per share by delivering $0.85, resulting in a surprise of +19.72%. Over the past four quarters, the company has beaten consensus EPS estimates twice [13][14]. Industry Comparison - Another company in the Zacks Medical - Generic Drugs industry, Supernus Pharmaceuticals (SUPN), is expected to report earnings of $0.47 per share for the same quarter, indicating a year-over-year decline of 55.7%. Revenues are projected to be $182.06 million, up 3.6% from the previous year [18]. - The consensus EPS estimate for Supernus has been revised 14.3% higher in the last 30 days, but its Earnings ESP is 0.00%, combined with a Zacks Rank of 1, making it difficult to predict a beat on the consensus EPS estimate [19][20].